Cumberland Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cumberland Pharmaceuticals Inc. on April 28, 2025. The report details the results of the Company's annual meeting of shareholders held on April 22, 2025, in Nashville, Tennessee.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and shareholder voting results.
Material Changes
No material financial changes or operational updates were reported in this filing. The document serves to disclose the outcome of specific shareholder votes.
Management Commentary and Governance Outcomes
Shareholders approved the following matters at the annual meeting:
- Election of Directors: Three Class III Directors were elected with overwhelming support.
- Appointment of Auditors: Carr, Riggs & Ingram, LLC was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Voting Results:
| Proposal / Director | Votes For | Votes Against | Votes Withheld | Abstentions | % in Favor |
|---|---|---|---|---|---|
| Gordon R. Bernard | 8,330,433 | 0 | 121,256 | 0 | 98.6% |
| Joseph C. Galante | 8,381,649 | 0 | 70,050 | 0 | 99.2% |
| A.J. Kazimi | 8,416,517 | 0 | 35,182 | 0 | 99.6% |
| Appointment of Carr, Riggs & Ingram, LLC | 11,338,632 | 25,717 | 0 | 14,490 | 99.7% |
Investor Verification Checklist
- Verify the official appointment of Carr, Riggs & Ingram, LLC as the auditor for the 2025 fiscal year.
- Confirm the tenure and responsibilities of the newly elected Class III Directors: Gordon R. Bernard, Joseph C. Galante, and A.J. Kazimi.
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.